Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
India-US Trade Talks Advance Toward $500 Billion Goal Amid Ongoing Negotiations 
Japan Inflation Rises in March Amid Energy Price Surge and Middle East Tensions 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Stock Futures Dip as S&P 500, Nasdaq Hit Record Highs Amid Rising U.S.-Iran Tensions 
Iran Tightens Grip on Strait of Hormuz as Oil Prices Surge 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Asian Stocks Mixed as Tech Shares Decline While Japan’s Nikkei Hits Record High 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Oil Prices Surge Amid Escalating U.S.-Iran Conflict and Strait of Hormuz Tensions 
Gold Prices Edge Higher Amid Middle East Tensions and Ceasefire Uncertainty 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Oil Prices Rise as U.S.-Iran Tensions and Strait of Hormuz Disruptions Persist 
Merck & Co Inc. revealed on Monday, Nov. 21, that it has acquired Imago BioSciences for $1.35 billion. The New Jersey-based pharmaceutical company is offering $36 per share in cash for the acquisition of the biotech firm, and this amount is said to be equivalent to almost 107% premium to its last closing price.
According to Reuters, this deal between Merck & Co. and Imago BioSciences drug developer is expected to close within the first quarter of 2023. This agreement is said to have opened several markets for the company.
Amid the buyout, Imago BioSciences is currently developing drugs for the treatment of diseases related to born marrow. The company uncovered a small molecule and brought it to phase 2 stage to find stronger evidence that suppressing lysine-specific demethylase 1 (LSD1) lowers the symptoms of myeloproliferative neoplasms or MPNs, which is a group of bone marrow cancers that can potentially develop into acute myeloid leukemia.
If the biotech firm is correct with its findings, bomedemstat will improve the results in the MPNs essential thrombocythemia, myelofibrosis, and polycythemia vera. Merck is interested in this discovery and bought into the idea; thus, it needs to buy Imago BioSciences.
Under the terms of the deal, through a subsidiary, Merck & Co. will set in motion a tender offer to buy all the remaining shares of Imago. Then again, it was noted that the closing of the offer will still be subject to some conditions, such as the expiration of the waiting period. According to the Hart-Scott-Rodino Antitrust Improvements Act, the tender of shares must represent a majority of Imago’s total number of available shares and other standard conditions.
“We continue to invest in our pipeline with a focus on applying our unique capabilities to unlock the value of breakthrough science for the patients we serve,” Merck’s president and chief executive officer, Robert M. Davis, said in a press release. “This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology.”
Dr. Hugh Y. Rienhoff, Jr., Imago BioSciences’ founder and CEO, also commented, “This milestone is a testament to more than a decade of pioneering research by Imago scientists and the entire Imago team’s unwavering dedication to improving the lives of patients. this agreement leverages Merck’s industry-leading clinical development expertise to maximize the therapeutic potential of bomedemstat while providing important value for shareholders.”
